Serum S100A8/S100A9 is associated with increased risk of brain metastasis in patients with inflammatory breast cancer.

Saved in:
Bibliographic Details
Title: Serum S100A8/S100A9 is associated with increased risk of brain metastasis in patients with inflammatory breast cancer.
Authors: Villodre ES; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston TX.; Department of Morgan Welch Inflammatory Breast Cancer Clinic and Research Program, The University of Texas MD Anderson Cancer Center, Houston TX., Song J; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston TX., Hu X; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston TX.; Department of Morgan Welch Inflammatory Breast Cancer Clinic and Research Program, The University of Texas MD Anderson Cancer Center, Houston TX., Gomez K; Department of Biological Sciences, The University of Texas at Brownsville, TX, USA., Cohen EN; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston TX., Reuben JM; Department of Morgan Welch Inflammatory Breast Cancer Clinic and Research Program, The University of Texas MD Anderson Cancer Center, Houston TX., Nasrazadani A; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston TX., Lim B; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston TX., Tripathy D; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston TX.; Department of Morgan Welch Inflammatory Breast Cancer Clinic and Research Program, The University of Texas MD Anderson Cancer Center, Houston TX., Woodward WA; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston TX.; Department of Morgan Welch Inflammatory Breast Cancer Clinic and Research Program, The University of Texas MD Anderson Cancer Center, Houston TX., Krishnamurthy S; Department of Pathology, and The University of Texas MD Anderson Cancer Center, Houston TX.; Department of Morgan Welch Inflammatory Breast Cancer Clinic and Research Program, The University of Texas MD Anderson Cancer Center, Houston TX., Debeb BG; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston TX.; Department of Morgan Welch Inflammatory Breast Cancer Clinic and Research Program, The University of Texas MD Anderson Cancer Center, Houston TX.
Corporate Authors: MDACC Inflammatory Breast Cancer Team
Source: MedRxiv : the preprint server for health sciences [medRxiv] 2026 Jan 22. Date of Electronic Publication: 2026 Jan 22.
Publication Type: Journal Article; Preprint
Journal Info: Country of Publication: United States NLM ID: 101767986 Publication Model: Electronic Cited Medium: Internet NLM ISO Abbreviation: medRxiv Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
DOI:10.64898/2026.01.21.26344294